has remained intriguing. Indeed, a direct biochemical comparison of DUB and AcT activities in CE family proteins has not yet been performed. We used our panel of purified bacterial CE enzymes from a range of pathogens alongside their catalytically inactive variants (Fig. 1a) to test for DUB activity by monitoring cleavage of K63-linked diubiquitin (diUb) (Fig. 1b) . In parallel, we tested for AcT activity by monitoring auto-acetylation via radioisotope incorporation following incubation with 14 C Acetyl-Coenzyme A (Fig. 1c ). This analysis revealed Salmonella SseL, Escherichia ElaD, Shigella ShiCE, and Rickettsia RickCE to be dedicated DUBs, and identified Legionella LegCE, Yersinia YopJ, and Salmonella AvrA as dedicated AcTs.
Remarkably, Chlamydia ChlaDUB1 could perform both DUB and AcT reactions, seemingly using the same catalytic Cys residue (compare Fig. 1b,c) . ChlaDUB1 is phylogenetically distinct from the YopJ-like family 11 , but showed similar rates of auto-acetylation compared with YopJ and AvrA (although YopJ acetylation of its substrate MEK2 (ref. 8 ) is markedly faster, see Supplementary  Fig. 1a-c) . Importantly, ChlaDUB1 auto-acetylation occurs at Lys residues ( Supplementary Fig. 1d ,e), whereas YopJ-like family members predominantly target Ser/Thr residues [7] [8] [9] . Furthermore, ChlaDUB1 AcT activity is not regulated by phytic acid (inositol hexakisphosphate, IP6) ( Supplementary Fig. 1f,g ), in contrast to YopJ-like enzymes 16, 17 . This identified ChlaDUB1 as a bona fide Lys-AcT in addition to being a Lys63-specific DUB.
To explain how ChlaDUB1 could perform two seemingly disparate chemical reactions, namely deubiquitination-a hydrolysis reaction, and acetylation-a condensation reaction, we determined crystal structures of the enzyme bound to Ub, and bound to Coenzyme A (CoA) at 1.9 Å and 2.1 Å resolution, respectively ( Fig. 1d and Supplementary Table 1 ). The structures showed hardly any conformational changes between each other, or in comparison with previous apo structures (pdb id 5HAG 11 , 5B5Q 15 ) with overall root mean squared deviations < 1 Å (Fig. 1d and Supplementary Fig. 2a ), but revealed distinct binding sites for Ub and CoA.
The ChlaDUB1~Ub structure ( Supplementary Fig. 2b ) was obtained using the Ub activity-based probe Ub-propargylamide (Ub-PA), which covalently links one Ub molecule into the enzymatic S1 site ( Supplementary Fig. 3 ). ChlaDUB1 forms similar interactions with Ub compared with other CE proteases
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The ChlaDUB1~CoA structure ( Supplementary Fig. 2e ) revealed a disulfide bridge between the cofactor's cysteamine and the catalytic Cys, and identified a charge-complementary binding site for CoA near the active site ( Supplementary Fig. 2f ). The ChlaDUB1 CoA-binding site is distinct from the CoA-binding sites of the YopJ-like effector HopZ1a 16 and arylamine N-acetyltransferases (NATs) 21 ( Supplementary Fig. 2g ,h), and is also removed from the Ub-binding site ( Supplementary Fig. 3 ).
Both structures together reveal the importance of an inserted helix that is unique to ChlaDUB1 and not present in other CE enzymes from bacteria, viruses or eukaryotes; we had previously annotated this element as Variable Region 3 (VR-3) 11 . One face of this VR-3 helix contacts the adenosine and phosphate groups of the CoA molecule (Fig. 2a,b) . Remarkably, the opposite face of the VR-3 helix binds the Ile36-patch of Ub (Fig. 2a,b and Supplementary Fig. 2i ). This arrangement enables both DUB and AcT activities to utilize the same active site ( Fig. 1d and Supplementary Fig. 4a,b) , via spatially separated, independent binding sites for Ub and CoA. Consistently, Ub compromises AcT activity, but when the Ub C-terminus is missing, auto-acetylation is restored (Supplementary Fig. 4c ). Separate binding sites for Ub and CoA further enabled us to uncouple DUB and AcT activity. ChlaDUB1 AcT activity was strongly diminished by mutation of K268E (VR-3), or G272E without affecting DUB activity. In contrast, DUB activity was abrogated by I267R (VR-3) or I225A mutation, yet these mutants did not affect auto-acetylation (Fig. 2a,c and Supplementary Fig. 5a ).
The VR-3 helix is central to dual activities in C. trachomatis (C.t.) ChlaDUB1 and present in all Chlamydia ChlaDUB homologues, such as ChlaDUB of C. abortus (C.a.), a cattle pathogen that is transmissible to humans. A 1.5 Å crystal structure of C.a. ChlaDUB confirmed the register of the predicted VR-3 helix as shown in the sequence alignment (Fig. 2d, Supplementary  Fig. 5d ,e and Supplementary Table 1) . Importantly, the Ub-and CoA-coordinating residues within VR-3 are not jointly conserved (Fig. 2d) , and we hypothesized that C.t. ChlaDUB2 should be a dedicated DUB, while C.a. ChlaDUB should be a dedicated AcT. Indeed, these predictions could be confirmed biochemically (Fig. 2e,f and Supplementary Fig. 5b,c) . Together, our data strongly suggested that Chlamydia species evolved ChlaDUB effectors with dual activities and potentially multiple functions. 
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Functional characterization of Chlamydia effectors has remained challenging, mostly due to the rudimentary tools available for genetic manipulation of Chlamydia
22
. Nonetheless, we set out to uncover roles for the DUB/AcT ChlaDUB1 and the dedicated DUB ChlaDUB2 utilizing mutant strains harbouring catalytically inactive ChlaDUB1 and ChlaDUB2 variants. One strain, containing a mutation leading to an amino acid substitution in the ChlaDUB2 catalytic His residue (H203Y) that inactivates the enzyme ( Supplementary  Fig. 6a ), was identified from a collection of chemically mutagenized C. trachomatis strains 23 . 
14
C acetylation assay with the ChlaDUB orthologues from C. trachomatis (C.t. ChlaDUB2) and C. abortus (C.a. ChlaDUB). f, Deubiquitinase assay monitoring K63-linked diUb cleavage by the Chlamydia ChlaDUB orthologues. Gels in e and f are representative of triplicate experiments. All uncropped gels are shown in Supplementary Fig. 10 . g, Schematic depicting how DUB and AcT functions can be separated either by structure-guided mutation or evolution as represented by the ChlaDUB orthologues. Wild-type Tables 2 and 3 ). For ChlaDUB1, we obtained a recently characterized ChlaDUB1 mutant strain 15 generated by transposon mutagenesis that introduced an early stop codon before the catalytic Cys residue (cdu1-Tn) ( Fig. 3a and Supplementary Table 2) .
The ChlaDUB1 and ChlaDUB2 loss of function strains left us in the privileged position of assessing the effects of either enzyme on host biology, and on contributions to Chlamydia infection. The cdu1-Tn mutant strain did not significantly reduce the number of infectious progeny in HeLa cells compared with a wild-type strain. This was markedly different in A549 cells, a human adenocarcinomic lung epithelial cell line, in which infection with the cdu1-Tn mutant strain reduced progeny by 90% (Fig. 3b) . The latter was comparable to the effect of this strain in vivo using a transcervical mouse model of infection, whereas primary human fimbriae cells showed a bacterial growth defect only after prior stimulation with interferon-γ 15 . Surprisingly, the Cdu2-H203Y strain showed little to no growth defect in either HeLa or A549 cell lines compared with its two parental strains (see Methods) ( Fig. 3b) , suggesting that ChlaDUB1, with its additional AcT activity, may play a unique role in Chlamydia infection.
Next, we inspected infected cells by confocal microscopy. A prominent feature of Chlamydia-infected cells is the fragmentation and subsequent redistribution of the Golgi apparatus into ministacks that surround the pathogen-containing vacuole (termed the inclusion) at approximately 20 hours post infection 24, 25 . Because ChlaDUB1 and ChlaDUB2 are actively expressed and secreted at this time post infection and have been shown to localize to the outside of the inclusion membrane where they could interact with neighbouring organelles 15, 26 , we used our cdu1-Tn and Cdu2-H203Y mutant strains to test for a contribution to Golgi redistribution following infection. Remarkably, at 26 hours post infection, both the cdu1-Tn and Cdu2-H203Y mutant strains showed a dramatic impairment in redistribution of the Golgi apparatus (Fig. 3c-f and Supplementary  Fig. 6b-e) . Since both ChlaDUB1 and ChlaDUB2 mutant strains affected host Golgi redistribution, this strongly suggested that DUB activity is required in this process. Moreover, the comparable individual impact of each mutant strain on Golgi redistribution (Fig. 3e,f) indicates either non-redundant roles for each DUB, or a strict dose dependency on DUB activity introduced by Chlamydia to invoke the observed cell biological effect. Finally, a similar extent of Golgi redistribution was seen in A549 but also HeLa cells, contrasting with the different impact of ChlaDUB mutant strains on bacterial growth rates (compare Fig. 3c-f with Fig. 3b ). This lack of correlation had been observed previously in HeLa cells, for example with InaC that regulates Golgi redistribution without impacting the generation of bacterial progeny 23 . Our data suggested that ChlaDUB1 and ChlaDUB2 may have unrecognized roles in manipulating Golgi morphology and dynamics, which was corroborated in a simplified system (Fig. 4a) . Strikingly, we found that Golgi fragmentation was readily induced by sole expression of either ChlaDUB1 or ChlaDUB2 in HeLa cells (Fig. 4b, Supplementary Fig. 7a,b and Supplementary Fig. 8a,b) . Expression of wild-type ChlaDUB1 and (to a lesser extent) ChlaDUB2 resulted in significant Golgi fragmentation as measured either by the number or the size of Golgi-stained puncta. Importantly, active site mutations eliminated this effect, which was again more pronounced for ChlaDUB1 (Fig. 4c,d , Supplementary  Fig. 7c,d and Supplementary Fig. 8c,d ). All ChlaDUB1 constructs showed an enriched localization to the Golgi apparatus, indicating that the introduced mutations exclusively affect activity (Fig. 4b and Supplementary Fig. 7b ). ChlaDUB2 appeared to primarily localize to the endoplasmic reticulum ( Supplementary Fig. 8e ), which could explain its reduced ability to induce Golgi fragmentation compared with ChlaDUB1. Using our structure-guided mutations that separate ChlaDUB1 DUB and AcT functions (Figs. 2g and 4a) , the Golgi fragmentation could be assigned as a DUB-dependent effect. A DUB-deficient I267R mutant was as defective in Golgi fragmentation as a catalytically inactive C345A construct, while an AcTdeficient ChlaDUB1 K268E mutant retained its Golgi fragmenting capabilities (Fig. 4b-d and Supplementary Fig. 7a-d ).
This unveils a remarkable case of protein moonlighting 27 , wherein a bacterial effector, C. trachomatis ChlaDUB1, performs two distinct enzymatic activities within its catalytic site, leading to separable cellular functions. Single amino acid substitutions can toggle between the activities, and this is used by closely related orthologues and paralogues in this enzyme family to modulate function (Fig. 2g) . We further establish that the DUB activities present in ChlaDUB1, and also in the dedicated DUB paralogue ChlaDUB2, are necessary and sufficient for the fragmentation of the host Golgi apparatus, a prerequisite to Golgi redistribution around the Chlamydia inclusion. This adds ChlaDUB1 and ChlaDUB2 to the limited list of effectors and host factors implicated in this striking cell biological phenomenon [23] [24] [25] 28, 29 (see Supplementary Fig. 9 ). In overexpression studies, ChlaDUB1 has also been implicated with inhibition of NF-κ B signalling 13 and cell death 15 , and it is tempting to speculate that some of these effects are conferred by the AcT activity of ChlaDUB1. While this requires further study, the importance of ChlaDUB1 for Chlamydia infectivity 15 and its unique enzymatic nature make it an interesting candidate for future Chlamydia-targeted therapeutics.
Methods
Cloning and molecular biology. Generation of Salmonella Typhimurium SseL, Chlamydia trachomatis ChlaDUB1, Escherichia coli ElaD, Shigella flexneri ShiCE, Rickettsia bellii RickCE, Legionella pneumophila LegCE, Yersinia pestis YopJ, and Salmonella Typhimurium AvrA constructs have been described previously 11 . Sequences for Chlamydia trachomatis ChlaDUB2 and Chlamydia abortus ChlaDUB were obtained via gene synthesis (Life Technologies). Following amplification with KOD polymerase (EMD Millipore), the genes were inserted into the pOPIN-B or pOPIN-GFP vector 30 with the In-Fusion cloning method (Takara Bio USA). All mutagenesis was performed using the Quikchange method (Agilent).
Protein expression and purification. The expression and purification of SseL (24-340), ElaD (2-407), ShiCE (2-405), RickCE (378-691), LegCE (141-360), YopJ (1-288) and AvrA (1-288) has been described previously 11 . C.t. ChlaDUB1 (130-401), C.t. ChlaDUB2 (80-339) and C.a. ChlaDUB were expressed in E. coli Rosetta2 pLacI cells (Novagen) at 18 °C for 20 h following induction with 0.2 mM IPTG at an absorbance A 600 nm of 0.8-1.0. Cells were harvested in 25 mM Tris buffer (pH 7.4), 200 mM NaCl, 2 mM ß-mercaptoethanol (Buffer A) and subjected to one freeze-thaw cycle. EDTA-free Complete protease inhibitor tablets (Roche), DNase and Lysozyme were added prior to lysis by sonication. The resulting lysate was centrifuged at 35,000g for 25 min, and applied to Talon resin (Takara Bio USA). The resin was washed with Buffer A thoroughly prior to elution with Buffer A containing 250 mM imidazole. During overnight dialysis back to Buffer A at 4 °C, the His-tag was cleaved with His-3C protease. Following a reverse affinity step over regenerated Talon resin, the resulting protein was then concentrated (10,000 MWCO, EMD Millipore) and applied to a gel filtration column (Superdex75, GE Healthcare) equilibrated in 25 mM HEPES (pH 8.0), 150 mM NaCl, 5 mM DTT. Pure protein-containing fractions were concentrated, aliquoted and flash-frozen for storage at − 80 °C.
Deubiquitinase assays. All enzymes were diluted to a '× 2' concentration in 25 mM Tris (pH 7.4), 150 mM NaCl, 10 mM DTT and allowed to fully reduce for 20 min at room temperature. Then 6 µ M diUb stocks were prepared in 100 mM Tris (pH 7.4), 100 mM NaCl, 10 mM DTT and mixed 1:1 with × 2 enzyme prior to incubation at 37 °C. Samples were quenched in reducing LDS sample buffer (ThermoFisher), resolved by SDS-PAGE, and visualized using silver stain (BioRad).
Ub/Ubl KG-TAMRA protease assays were performed as described previously , PerkinElmer) at 37 °C for the indicated time. The panel shown in Fig. 1 and all subsequent assays with YopJ or AvrA additionally included 200 nM inositol hexakisphosphate (IP6). Reactions were quenched with reducing LDS sample buffer (ThermoFisher) and resolved by SDS-PAGE prior to staining with Coomassie. Gels were then dried and exposed to a Phosphor screen for several days prior to imaging on a Typhoon scanner (GE Healthcare). The 14 C autoradiography intensity was quantified using ImageJ 31 and normalized to the Coomassie stain signal.
Protein crystallization. The ChlaDUB1 (130-401)~Ub complex was purified by gel filtration following an overnight reaction at room temperature with 2-fold molar excess Ub-PA suicide probe 32 . Native ChlaDUB1~Ub crystals were obtained using protein prepared in 25 mM Tris (pH 7.4), 125 mM NaCl, 4 mM DTT and crystallized at 10 mg ml -1 in 0.1 M MES (pH 6.0), 20% PEG 6000, with a 400 nl sitting drop at 1:1 protein:precipitant ratio. SeMet ChlaDUB1~Ub crystals were obtained using protein at 7 mg ml -1 in 0.1 M HEPES (pH 7.1), 18% PEG 8 K, with a 200 nl sitting drop at 1:1 protein:precipitant ratio. The ChlaDUB1~CoA complex was crystallized by the addition of 2 mM CoA to 12 mg ml -1 ChlaDUB1, and mixing with 0.1 M HEPES (pH 7.2), 20% PEG 8000 at a 1:1 protein:precipitant ratio in a 400 nl sitting drop. C. a. ChlaDUB (108-377) was prepared in 25 mM HEPES (pH 8.0), 150 mM NaCl, 5 mM DTT and crystallized in 0.1 M Tris (pH 7.0), 0.2 M calcium acetate, 20% PEG 3000 with a 400 nl sitting drop at 1:1 protein:precipitant ratio. All crystals were cryoprotected with mother liquor containing 25% glycerol. Cryoprotectant for ChlaDUB1~CoA crystals also contained 5 mM CoA.
Data collection, structure determination and refinement. Data were collected at 100 K at the Diamond Light Source (DLS) beam lines I02, I03 and I04 (see Supplementary Table 1) . Data collections were performed at 0.9798, 0.9795 and 0.9794 Å wavelengths for the ChlaDUB1~Ub, ChlaDUB1~CoA and C.a. ChlaDUB structures, respectively. Integration and scaling were performed using XDS 33 and Aimless
34
, respectively. The ChlaDUB1~Ub structure was solved experimentally using a SeMet SAD dataset with PHENIX AutoSol and AutoBuild [35] [36] [37] . ChlaDUB1~CoA and C.a. ChlaDUB structures were solved using molecular replacement in Phaser 38 using the apo ChlaDUB1 structure (pdb id 5HAG). Iterative rounds of model building and refinement were performed using COOT 39 and PHENIX 35 , respectively. Ramachandran statistics (favoured/allowed/ outliers) for the ChlaDUB1~Ub, ChlaDUB1~CoA and C.a. ChlaDUB structures were 97.2/2.8/0, 97.4/2.6/0 and 98.0/2.0/0, respectively. All figures were generated using PyMOL (www.pymol.org).
Cell lines. HeLa, A549 and Vero cell lines were obtained from ATCC, where they were authenticated by morphology, karyotyping and short tandem repeat analyses. Stocks were routinely tested and confirmed negative for mycoplasma contamination.
Chlamydia growth conditions and infections. HeLa, A549 and Vero cells were grown in high-glucose DMEM supplemented with L-glutamine, sodium pyruvate (Gibco, Life Technologies) and 10% FBS (Mediatech, CellGro), at 37 °C in a 5% CO 2 humidified incubator. All cells infected with Chlamydia were centrifuged at 3,500 r.p.m. for 30 min at 10 °C immediately on infection. Table 2) were derived from C. trachomatis LGV biovar L2 434/Bu (wild-type). The cdu1-Tn strain was provided by Scott Hefty (University of Kansas) and is described previously 15 . The cdu2-G607A (Cdu2-H203Y) allele was identified in a collection of chemically mutagenized C. trachomatis L2 434/Bu strains by whole-genome sequencing of a collection of pooled mutant strains 23 . Strain CTL2M467 was identified as harbouring the cdu2-G607A single nucleotide variant (SNV) by Sanger sequencing of the cdu2 (CTL0246) locus. Vero cells seeded in a 6-well plate were infected with CTL2M467. At 48 hours post infection (hpi), cell monolayers were lysed by hypotonic lysis, lysates sonicated, and bacterial cells collected by centrifugation at 14,000 r.p.m. for 15 min at 4 °C. Bacterial cell pellets were resuspended in 1X DNAse I buffer (New England Biolabs) and treated with 4 units of DNAse 1 (New England Biolabs) for 1 h at 37 °C to deplete co-purifying Vero DNA. Following a wash with PBS buffer, total DNA was isolated with a DNA isolation kit (DNeasy tissue and blood kit, Qiagen) following the manufacturer's instructions.
Chlamydia strains. All Chlamydia strains (Supplementary
One μ g of CTL2M467-enriched DNA was fragmented with NEBNext dsDNA Fragmentase (New England Biolabs) and DNA sequencing libraries prepared with a NEBnext DNA Library Prep Kit for Illumina according to the manufacturer's Letters NaTUre MiCrOBiOLOGy instructions. Libraries were sequenced with the MiSeq DNA Sequencing Platform (Illumina, Inc.) at the Duke University IGSP sequencing facility. Genome assembly and SNV identification was performed with Geneious version 6 (Biomatters, http://www.geneious.com/). The C. trachomatis L2 434/Bu genome (GenBank no. NC_010287) was used as a reference sequence. All SNVs identified (Supplementary Table 3 ) and spectinomycin (200 μ g ml -1 ) was added to infected cells as previously described 40 and the cells incubated for 14 days. Recombinant strains were isolated from 24 individual plaques and expanded in Vero cells. All recombinant strains were genotyped by PCR for the presence of CTL2M467 parental nonsynonymous SNVs (Supplementary Table 3 ). Recombinant strain number 22 (M467 rs22) was found to harbour only the parental cdu2-G607A mutation (Cdu2-H203Y). Chlamydia strains were maintained as frozen stocks in SPG buffer.
Chlamydia growth assays. HeLa and A549 cells were seeded in wells of two 96-well plates (input and output plates). Cells were infected with Chlamydia strains at an m.o.i. of 0.6. At 24 hpi, infected cells in the input plate were fixed with icecold methanol and stored in PBS. At 48 hpi, crude lysates in SPG were prepared from infected cells in output plates and a series of 1:10 dilutions were used to immediately infect corresponding HeLa or A549 cells seeded in wells of a 96-well plate. At 24 hpi, cells were fixed with ice-cold methanol. Fixed cells were stained with rabbit anti-Slc1 41 and Hoechst. Images from stained cells were captured on an EVOS cell imaging system (ThermoFisher scientific) with a 20X objective. Inclusion forming units (IFUs) were quantified using ImageJ (NIH). Output IFUs from each Chlamydia inoculum were normalized to their respective input IFUs. Chlamydia IFU production was measured from three independent biological replicates. Golgi redistribution quantification. For each Z-stack, maximum intensity Z-projections were generated with ImageJ (NIH). The length of Golgi (defined by GM130 staining) distributed around Chlamydia inclusions and the length of each inclusion perimeter (defined by Slc1 staining) were measured using the line tool from ImageJ (NIH). The ratio of Golgi length to inclusion perimeter length was determined, and values expressed as a percentage. Three independent experiments were performed to assess Golgi distribution. Golgi distribution was assessed from 6 fields for a total of 90 cells per independent experiment.
Visual and quantitative analysis of Golgi redistribution around
High-resolution imaging. Standard deviation Z-projections of captured images (see above) were generated and images minimally processed with ImageJ (NIH).
ChlaDUB expression in mammalian cells. Imaging. HeLa cells grown on glass coverslips were transfected with 1 µ g of plasmid using Genejuice (EMD Millipore). At 23 h post transfection, cells were fixed with 4% paraformaldehyde, immunostained for GM130 (BD Biosciences 610822). Nucleic acids were stained with DAPI. Images were collected on a Nikon Eclipse Ti microscope with a Super Plan Fluor ELWD 40XC objective or a 3i Marianas spinning disk inverted confocal microscope with a 63X oil objective and a CMOS camera (Hamatsu). The images were then processed using SlideBook software and Photoshop CS4 Version 11.0 (Adobe).
Quantification of Golgi fragmentation. Images were converted from 16-bit to 8-bit binary using Fiji. Following selection of the region of interest, the number and surface area of Golgi-stained particles were quantified using the Analyze Particles tool of Fiji. A minimum of three independent experiments were performed to assess Golgi fragmentation, each consisting of ~65 counted cells. Multinucleated cells, as well as cells that were cycling through mitosis, were excluded from the analysis.
Western blotting. HeLa cells were transfected with 1 µ g of plasmid using Genejuice (EMD Millipore). At 23 h post transfection, cells were lysed in RIPA buffer and the protein amount was assessed using the Pierce BCA Protein Assay Kit (Thermo). Then 20 µ g of lysates were resolved by SDS-PAGE and transferred onto nitrocellulose. Membranes were blocked in 5% milk/TBST for 1 h and probed for GFP (sheep, 1:1,000, made in-house) and actin (rabbit, 1:10,000, Sigma A2266) for 1 h at room temperature. The IRDye 680LT Donkey anti-Rabbit IgG (LI-COR 926-68023) and IRDye 800CW Donkey anti-Goat IgG (cross-reacts with sheep IgG, LI-COR 926-32214) secondary antibodies were used at a concentration of 1:10,000 in 5% milk. Membranes were scanned using a LI-COR CLx Odyssey system and the Image Studio software, and minimally processed in Photoshop CS4 Version 11.0 (Adobe).
Statistical analyses. All statistical analyses were performed using GraphPad Prism 7.0. Chlamydia growth assays were analysed using a two-tailed Welch's t-test. All other analyses used a two-tailed Mann-Whitney U-test. All experiments contained three biological replicates. Data from these replicates are either combined or plotted separately, as described in the figure legends.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
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Experimental design
Sample size
Describe how sample size was determined. Sample size was not predetermined, but standardised during analysis to improve comparisons across groups (see below). Sample sizes were set to a minimum value (as described in the figure and methods) after which the inclusion of additional data had no affect on median values.
Data exclusions
Describe any data exclusions. Biological data sets were set to a consistent number of data points in an unbiased fashion to normalise statistical power across groups. Exclusion parameters were not predetermined, but applied randomly such that median values were not affected.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful, and data from replicate experiments are shown where appropriate.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was not required in our study as all of our experiments are highly controlled and quantitative.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Images used for the quantification of Golgi fragmentation following Chlamydia infection were blinded prior to analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
